Novel approaches including gene editing are creeping towards approval.
A front-line trial yields a positive result two years after the drug got a US complete response letter.
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
Merus regains some lost pride while Bicycle rides to even greater heights.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.